|
1.
|
|
7 p, 267.3 KB |
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials
/
Allan, John N. (Weill Cornell Medicine) ;
Shanafelt, Tait (Stanford University Medical Center) ;
Wiestner, Adrian (National Heart, Lung, and Blood Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
O'Brien, Susan M. (University of California Irvine) ;
Li, Jianling (Pharmacyclics LLC) ;
Krigsfeld, Gabriel (Pharmacyclics LLC) ;
Dean, James P. (Pharmacyclics LLC) ;
Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ;
Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 -  10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953
|
|
|
2.
|
|
15 p, 607.8 KB |
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain : MOREL study
/
Rubio-Viqueira, Belen (Department of Medical Oncology. Quirónsalud Madrid Hospital. Pozuelo de Alarcón) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ;
Estévez, Sergio Vázquez (Hospital Universitario Lucus Augusti (Lugo)) ;
Córdoba Ortega, Juan Felipe (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Maiques, Inmaculada Maestu (Hospital Universitari Doctor Peset (València)) ;
González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Cordellat, Ana Blasco (Hospital General Universitario de Valencia) ;
Valdivia-Bautista, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Arenas, Carmen González (Department of Medical Oncology. Msd) ;
Sánchez Torres, José Miguel (Hospital Universitario de la Princesa (Madrid))
Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods: Multicenter, retrospective study. [...]
2021 - 10.2217/lmt-2021-0008
Lung Cancer Management, Vol. 10 Núm. 4 (december 2021) , p. LMT53
|
|
|
3.
|
|
16 p, 758.5 KB |
Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression : A network meta-analysis
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Marquez-Medina, Diego (Hospital Universitario Miguel Servet (Saragossa)) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Casal-Rubio, Joaquín (Hospital Álvaro Cunqueiro (Vigo)) ;
Moran-Bueno, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Pérez-Parente, Diego (Medical Affairs Department. Roche Farma S.A) ;
Ruiz-Gracia, Pedro (Medical Affairs Department. Roche Farma S.A) ;
Arroyo, Marta Marina (Medical Affairs Department. Roche Farma S.A) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid))
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selec-tion of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). [...]
2021 - 10.3390/jcm10071365
Journal of clinical medicine, Vol. 10 Núm. 7 (april 2021) , p. 1365
|
|
|
4.
|
|
15 p, 909.6 KB |
European Registry on Helicobacter pylori Management : Effectiveness of First and Second-Line Treatment in Spain
/
Caldas, María (Instituto de Investigación Hospital Universitario de la Princesa) ;
Pérez-Aisa, Ángeles (Agencia Sanitaria Costa del Sol (Andalusia)) ;
Castro-Fernández, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Bujanda, Luis (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Lucendo, Alfredo J. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Rodrigo-Sáez, Luis (Hospital Universitario Central de Asturias) ;
Huguet, José María (Hospital General Universitario de Valencia) ;
Pérez-Lasala, Jorge (Hospital Universitario HM Sanchinarro (Madrid)) ;
Molina-Infante, Javier (Hospital San Pedro de Alcántara) ;
Barrio, Jesús (Hospital Universitario Río Hortega (Valladolid)) ;
Fernández-Salazar, Luis (Hospital Clínico Universitario de Valladolid) ;
Lanas, Ángel (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Perona, Mónica (Gastroenterology Unit, Hospital Quirón Marbella) ;
Domínguez-Cajal, Manuel (Hospital General Universitario San Jorge (Osca, Aragó)) ;
Ortuño, Juan (Hospital Universitari i Politècnic La Fe (València)) ;
Gómez-Rodríguez, Blas José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Almela, Pedro (Consorci Hospitalari Provincial de Castelló) ;
Botargués, Josep María (Hospital Universitari de Bellvitge) ;
Núñez, Óscar (Digestive Service, Hospital Universitario Sanitas La Moraleja) ;
Modolell, Inés (Consorci Sanitari Hospital de Terrassa) ;
Gómez, Judith (Digestive Service, Complejo Asistencial Universitario de Burgos) ;
Ruiz-Zorrilla, Rafael (Hospital Sierrallana) ;
De la Coba, Cristóbal (Hospital Universitario de Cabueñes (Gijón)) ;
Huerta, Alain (Hospital de Galdakao (Usansolo, Biscaia)) ;
Iyo, Eduardo (Hospital Comarcal de Inca) ;
Pozzati, Liliana (Digestive Service, Hospital de Mérida (Extremadura)) ;
Antón, Rosario (Hospital Clínic Universitari (València)) ;
Barenys, Mercé (Hospital de Viladecans (Catalunya)) ;
Angueira, Teresa (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Fernández-Bermejo, Miguel (Digestive Service, Clínica San Francisco (Extremadura)) ;
Campillo, Ana (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Alcedo, Javier (Hospital de Barbastro) ;
Pajares-Villaroya, Ramón (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
Mego Silva, Marianela (Hospital Universitari General de Catalunya) ;
Bermejo, Fernando (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Dominguez-Jiménez, José Luis (Hospital Alto del Guadalquivir) ;
Titó, Llúcia (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Fernández, Nuria (Agencia Sanitaria Costa del Sol (Andalusia)) ;
Pabón-Carrasco, Manuel (Universidad de Sevilla) ;
Cosme, Ángel (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Mata-Romero, Pilar (Hospital San Pedro de Alcántara) ;
Alcaide, Noelia (Hospital Clínico Universitario de Valladolid) ;
Ariño, Inés (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Di Maira, Tommaso (Hospital Universitari i Politècnic La Fe (València)) ;
Garre, Ana (Instituto de Investigación Hospital Universitario de la Princesa) ;
Puig, Ignasi (Universitat de Vic) ;
Nyssen, Olga P. (Instituto de Investigación Hospital Universitario de la Princesa) ;
Megraud, Francis (Université de Bordeaux) ;
O'Morain, Colm (Department of Clinical Medicine, Trinity College Dublin) ;
P. Gisbert, Javier (Instituto de Investigación Hospital Universitario de la Princesa) ;
Universitat Autònoma de Barcelona
The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. [...]
2020 - 10.3390/antibiotics10010013
Antibiotics, Vol. 10 (december 2020)
|
|
|
5.
|
|
12 p, 744.6 KB |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
/
Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Safont, María José (Hospital General Universitario de Valencia) ;
Gallego, Javier (Hospital General Universitario de Elche) ;
García-Paredes, Beatriz (Hospital Clínico San Carlos (Madrid)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Dueñas, Rosario (Complejo Hospitalario de Jaén) ;
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Losa, Ferrán (Hospital General de l'Hospitalet) ;
Valladares Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ;
González, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ;
Aranda Aguilar, Enrique (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ;
Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202
|
|
|
6.
|
|
7 p, 242.6 KB |
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies
/
Boeckx, N. (University Hospital Antwerp (Bèlgica)) ;
Koukakis, R. (Biostatistics, Amgen Ltd) ;
Op de Beeck, K. (University Hospital Antwerp (Bèlgica)) ;
Rolfo, Christian (University Hospital Antwerp (Bèlgica)) ;
Van Camp, G. (University Hospital Antwerp (Bèlgica)) ;
Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Douillard, Jean-Yves (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ;
André, Thierry (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ;
Peeters, Marc (University Hospital Antwerp (Bèlgica))
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of oncology, Vol. 28 (april 2017) , p. 1862-1868
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
